Decreased serum interleukin-17 and increased transforming growth factor– β levels in subjects with metabolic syndrome (Chennai Urban Rural Epidemiology Study–95)

• Published in: Metabolism, clinical and experimental Vol. 60; no. 4; pp. 586 - 590
• Main Authors: Surendar, Jayagopi, Aravindhan, Vivekanandhan, Rao, Maradana Muralidhara, Ganesan, Anbazhagan, Mohan, Viswanathan
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.04.2011; Elsevier
• Subjects: Adult; adults; Anthropometry; anti-inflammatory activity; Asian Indians; Biological and medical sciences; blood glucose; Blood Glucose - metabolism; blood pressure; blood serum; Cholesterol - blood; Cholesterol, HDL - blood; Endocrinology & Metabolism; enzyme-linked immunosorbent assay; epidemiology; Feeding. Feeding behavior; Female; Fundamental and applied biological sciences. Psychology; guidelines; Humans; India; India - epidemiology; inflammation; interleukin-17; Interleukin-17 - blood; Logistic Models; Male; Medical sciences; Metabolic diseases; metabolic syndrome; Metabolic Syndrome - blood; Metabolic Syndrome - epidemiology; Middle Aged; Miscellaneous; National Cholesterol Education Program; Other metabolic disorders; risk factors; Rural Population; transforming growth factor beta; Transforming Growth Factor beta - blood; Triglycerides - blood; Vertebrates: anatomy and physiology, studies on body, several organs or systems; waist; World Health Organization; India; Endocrinopathy; Human; Rural environment; Urban environment; Transforming growth factor β; Metabolic diseases; Cardiovascular disease; Urban area; Metabolic syndrome; Epidemiology; Interleukin 17; Serum; Endocrinology
• ISSN: 0026-0495; 1532-8600; 1532-8600
• DOI: 10.1016/j.metabol.2010.06.003

The term metabolic syndrome (MS) refers to a conglomeration of many metabolic disorders. Recent studies suggest that inflammation plays a vital role in MS. There are however no data available on the recently characterized novel T-cell–derived cytokine interleukin (IL)-17 in MS; studies on the anti-inflammatory cytokine transforming growth factor (TGF)– β are also limited. The aim of the study was to look at IL-17 and TGF- β levels in subjects with and without MS. The study subjects were recruited from the Chennai Urban Rural Epidemiology Study (CURES), a population-based study in Chennai (formerly Madras) in southern India. Group 1 consisted of subjects without MS (non-MS) (n = 98) and group 2 consisted of subjects with MS (n = 156). MS was defined using the National Cholesterol Education Program Adult Treatment Panel III criteria modified for waist, according to the World Health Organization Asia Pacific guidelines. Serum IL-17 and TGF- β levels were estimated by enzyme-linked immunosorbent assay. Interleukin-17 levels were decreased ( P < .001) and TGF- β levels ( P < .001) were increased in subjects with MS compared to those without. With an increase in the number of metabolic risk factors, the IL-17 levels showed a decline, whereas the TGF- β levels showed an increase ( P < .001). With respect to individual components of MS, TGF- β and IL-17 showed a significant association with blood pressure and blood glucose even after adjusting for age and sex. We report that IL-17 levels are decreased, whereas TGF- β levels are increased, among Asian Indians with MS.